HA型血液灌流器与透析器串联对治疗慢性衰竭患者血脂的影响被引量：2

The effect of hemoperfusion (HP) on lipids in hemodialysis patients with chronic renal failure(CRF)

下载PDF

导出

摘要目的观察血液灌流对血液透析患者血脂[LP(α)]的影响。方法选取多个血液净化中心血液透析患者40例,比较单次血液透析串联血液灌流前后患者血脂的变化。结果慢性肾衰竭患者多数存在血脂代谢的紊乱,血液灌流后学[Lp(a)]以及甘油三酯(TG)的浓度下降,高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A(APOA)、载脂蛋白B(APOB)、总胆固醇(TC)的浓度无明显变化。结论血液灌流可以降低维持性血液透析患者的Lp(a)及TG,改善其脂代谢紊乱。 Objective To investigate the effect of hemoperfusion （HP）on lipids in hemodialysis patients with chronic renal failure（CRF）. Methods To compare the differences of lipids in 40 hemodialysis patients with CRF before and after the treatment of combined hemodialysis-hemoperfusion. Results Lipid disorders are common in patients with CRF. The levels of triglyceride（TG） and lipoprotein（a） [ Lp（a） ] in serum decreased after the treatment of combined hemodialysis-hemoperfusion. The levels of cholesterol（ TC）, high-density lipoprotein （ HDL）, low-density lipoprotein （ HDL）, low-density lipoprotein （ LDL）, apolipoprotein A （ APOA ）, apolipoprotein B （APOB） had no significant changes after treatment. Conclusion Hemoperfusion is a method of an effective treatment in dyslipidemia of hemodialysis patients.

作者李映杰

机构地区河南省商丘市第一人民医院血液净化中心

出处《中国实用医药》 2009年第15期23-24,共2页 China Practical Medicine

关键词血液灌流慢性肾衰竭血脂 Hemoperfusion CRF Lipids

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献11

1Mdnzani G,Bcrgcsin F,Ciuti R,et al.Lipoprotin abnomalitics in chronic renal failure and dialysis patients.Blood Purif,1996,14(3):262.
2Attman P-O,Samuelsson O,Alaupovic P:Lipoprotein metabolism and renal failure.Am J Kidney Dis,1993,21:573-591.
3Attman P-O,Samuelsson O,Moberly J,et al:Apolipop-rotein B-containing lipoprotein in renal failure:The relation to mode of dialysis.Kidney Int,1999,55:1536-1542.
4Eiscnberg S,Heiss G,Friedlander Y,et al.Compar-ison of plasma lipid,lipoproteins and dyslipopro-tincmia in Isratl and United States.Ac hernsclcr-osis,1986,59:63.
5Crassman MD,Hejka NJ,Paganai EP,et al.Lipop-roteinis an indenperdent risk factor of cardi-agscular dis(a)ease in hemodiasisly patients.Circul-ation,1992,16:475-482.
6Appel C.Lipid abnormalitics in renal disease.Kidney Int,1991,39:169.
7Gordon T,Castelli WP,Hjnland MC,et al.High den-sity lipoprotein as a protective factor against coronary heart disease:the Framingham Study.Am J Mied,1997,62:707.
8Attman P-O,Samuelsson O,Alanpovic P.Lipoprotein.metabolism and renal failure.Am J Kidney Dis,1999,21:573-591.
9P-O,Samuelsson O,Moberly J,et al.Apolipoprotein B-containing lipoprotein in renal failure:The relation to mode of dialysis.Kidney Int,1999,55:1536-1542.
10Bambauer R,Schid R,Latza R:Current topics on lo-wdensity lipoprotein apheresis.Therapenutic Apheresis,2001,5940:293-300.

二级参考文献3

1Bosch T. State of the art of lipid apheresis [J]. Artif Organs, 1996, 20 (4): 292-295
2Bosch T, Schmidt B, Kleophas W, et al. LDL hemoperfusion - a new procedure for LDL apheresis: first clinical application of an LDL adsorder compatibal with human whole blood[J]. ArtifOrgans, 1997, 21 (9): 977-982.
3Bosch T, Lennertz A, Kordes B, et al. Low density lipoperfusion by sirecy adsorption of lipoproteins from whole blood(DALI apheresis): clinical experience from a single center[J]. Ther Apher, 1999, 3 (3): 209-13.